Minutes - TRIPS Council - View details of the intervention/statement

H.E. Ambassador Dr. Lansana GBERIE
11 PARAGRAPH 8 OF THE MINISTERIAL DECISION ON THE TRIPS AGREEMENT ADOPTED ON 17 JUNE 2022

128.   Pakistan wishes to align itself with and echo the statement delivered by South Africa on behalf of the co-sponsors of the original TRIPS waiver decision. Pakistan would like to appreciate Dr Ngozi Okonjo-Iweala, Director-General of the WTO, and her efforts to achieve a Decision for the Membership on the TRIPS waiver. The Decision, even though not as ambitious as what the cosponsors would have liked, does underscore to the world at large the importance of a solution to the intellectual property-related challenges faced by many developing countries in their fight against the COVID-19 pandemic. 129.   The Decision, therefore, very aptly instructs Members in Paragraph 8 to decide on the extension of the Decision to therapeutics and diagnostics within six months, i.e. by 17 December 2022. Indeed, the solution to the overwhelming challenges faced by developing countries in their ongoing fight against COVID-19 is very limited if it remains confined to vaccines and does not address therapeutics and diagnostics. More specifically, while the pandemic is now entering a late stage, new variants will continue to develop and newer manifestations of the disease will come to surface, for instance long-term side effects, and repetitive infections with their own complications. In this phase, the need for going beyond vaccination and timely access to diagnostics and therapeutics has become crucial. 130.   This aspect has been duly recognized by the Directors General of the World Health Organization, World Intellectual Property Organization and the World Trade Organization in their joint statement underscoring a "commitment to universal, equitable access to COVID-19 vaccines, therapeutics, diagnostics, and other health technologies". The need for therapeutics and diagnostics in our efforts to detect, treat and contain the spread of COVID-19; and the various challenges in the IP system to achieve that aim, particularly challenges in achieving success through voluntary licensing mechanisms, has also been deliberated in great detail by the co-sponsors of the waiver in documents IP/C/W/670, IP/C/W/672 and IP/C/W/673. 131.   In terms of the work done by international organizations, WIPO's patent landscape report has explained these aspects in good detail alongside the WHO's strategic preparedness and response plan for COVID-19, which underscores diagnostics, particularly testing, as a key ingredient of a wholesome COVID-19 management strategy. 132.   This continuing need for a waiver for therapeutics and diagnostics is not new. It was pushed further during the negotiations on the waiver to allow more focus on vaccines at the time. This does not diminish the crucial importance of extending the waiver to diagnostics and therapeutics, which is even more necessary now. It is not just a technical or economic argument. It is an urgent moral responsibility that we as the membership owe to the world to demonstrate that we are actually interested in fighting the pandemic and saving human lives across the globe, that those lives in developing countries also matter, and that the waiver on vaccines is not mere window dressing. 133.   With this urgent need in mind, Pakistan fully supports the room document that has been circulated today on behalf of the co-sponsors. It clearly delineates a time frame for fulfilling our Ministerial mandate in a timely and effective manner. We urge Members to seriously consider this timeline ahead of us and work positively, constructively and meaningfully to deliver this decision within the stipulated time.

This Council took note of statements made and agreed to revert to this matter at its next meeting.
52. The Chair recalled that on 17 June 2022, the 12th Ministerial Conference had adopted a Ministerial Decision on the TRIPS Agreement which aimed to improve the capacity of developing country Members to produce and supply COVID-19 vaccines to other eligible Members. Paragraph 8 of the Decision provided that no later than six months from the date of this Decision, Members would decide on its extension to cover the production and supply of COVID-19 diagnostics and therapeutics.
53. The Chair recalled that barely three weeks had passed since the Ministerial Conference, which was concluded on 17 June, and that some were still recovering from the intense negotiations. He did not expect that Members had had time to prepare an in-depth position on the complex question of extending this decision to additional products, such as therapeutics and diagnostics. He also recalled from the negotiations during the 12th Ministerial Conference, that one reason for postponing a decision on extension to 6 months after adoption was that certain Members did not have a mandate to consider covering diagnostics and therapeutics, and that they would need the six months for discussions in their domestic arena to obtain such a mandate. He therefore assumed that Members would need time to prepare their engagement in this regard. and what could be expected at this first consideration of the topic would be a sharing of views on how best to approach the matter going forward.
54. The representatives of South Africa; Uruguay; Pakistan; Maldives; Ukraine; Egypt; Tanzania; Bangladesh; Indonesia; Argentina; Sri Lanka; China; India; the Russian Federation; Hong Kong, China; Chile; Bolivia, Plurinational State of; Australia; Brazil; the United Kingdom; Singapore; Norway; Canada; Japan; Korea, Republic of; the European Union; Malaysia; the United States; New Zealand; Nicaragua; Thailand; Switzerland; Panama; Mexico; and Peru took the floor.
55. The Chair said he had carefully listened to Members' views on how work in the Council should proceed on this very important matter. He said he recognized, as many delegations had, that this was a ministerial decision with a tight timeline and that the matter therefore needed to be treated with urgency. He also recognized that a number of delegations needed to consult with their capitals in order to agree on a proper framework for this decision.
56. He confirmed that there was a commitment by the Council to keep this matter alive until the decision was finalized. As regards reporting to the General Council, he noted that the next meeting was scheduled for 25-26 July, which was only 20 days away, and that therefore chances were slim that the TRIPS Council would have a lot to report by that time, given also that other meetings like the WIPO Assemblies were taking place in the meantime. Against this background, he suggested that it would be the best use of time if Members themselves brought their assessment of the discussions to the attention of the General Council during the next meeting.
57. With respect to continuing discussions, which he as Chair was committed to, he said it was important for meaningful discussions to start as soon as delegations were ready to engage on the substance of this rather complex question. It was important to carefully balance the urgent need to take this decision before the deadline in December as well as the time for domestic consultations necessary for some to proceed. In designing the proper framework on how to engage in this process it was also important to ensure that discussions were open, inclusive and transparent - as had been emphasized by many delegations.
58. He said that the experience of the negotiations leading to the Ministerial Decision suggested that, in the meantime, bilateral discussions and small group discussions could be extremely helpful to work out a proper framework around which a decision could be constructed by consensus – which remained an absolute requirement with respect to decisions by the Council and by the WTO. He therefore encouraged bilateral and small group meetings in the meantime, and said that this certainly remained a very active matter, that it would be properly discussed and the decision arrived at within the timeframes set by the ministerial decision.
59. This Council took note of statements made and agreed to revert to this matter at its next meeting.
IP/C/M/105, IP/C/M/105/Add.1, IP/C/M/105/Corr.1